Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 18/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 14/20 | 1.00 |
| ▸ | CHRM1 known ✓ | P11229 | 11/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL157068 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| SCHEMBL140527 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| SCHEMBL141476 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL4636715 | 0.89 | CHRM3 (0.81) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4668972 | 0.88 | CHRM3 (0.80) | CHRM3CHRM2CHRM1 | |
| SCHEMBL73028 | 0.85 | CHRM3 (0.76) | CHRM3CHRM2CHRM1 | |
| SCHEMBL2076295 | 0.85 | CHRM3 (0.76) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL4636585 | 0.83 | CHRM3 (0.71) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL4636595 | 0.82 | CHRM3 (0.70) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4636863 | 0.82 | CHRM3 (0.71) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2117542-A1 | COMBINATIONS OF BETA- 2 -ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | AstraZeneca AB (SE) | 2009-11-18 | — | — | EP | claimed |
| WO-2008096111-A1 | COMBINATIONS OF BETA- 2 -ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | WO | claimed |
| WO-2008096121-A1 | COMBINATIONS OF BETA-2-ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | WO | claimed |
| EP-2414376-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A STEROIDAL[3,2-C]PYRAZOLE DERIVATIVE AND A SECOND PHARMACEUTICALLY ACTIVE COMPOUND | AstraZeneca AB (SE) | 2012-02-08 | — | — | EP | disclosed |
| EP-2398792-A1 | TOSYLATE SALT OF A 5-PYRAZOLYL-2-PYRIDONE DERIVATIVE, USEFUL IN THE TREATMENT OF COPD | AstraZeneca AB (SE) | 2011-12-28 | — | — | EP | disclosed |
| EP-2379174-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | AstraZeneca AB (SE) | 2011-10-26 | — | — | EP | disclosed |
| US-20100261690-A1 | NOVEL COMBINATIONS | ASTRAZENECA R&D (SE) | 2010-10-14 | — | — | US | disclosed |
| WO-2010114472-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A STEROIDAL[3,2-C]PYRAZOLE DERIVATIVE AND A SECOND PHARMACEUTICALLY ACTIVE COMPOUND | ASTRAZENECA AB (SE) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010094964-A1 | TOSYLATE SALT OF A 5-PYRAZOLYL-2-PYRIDONE DERIVATIVE, USEFUL IN THE TREATMENT OF COPD | ASTRAZENECA AB (SE) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010071583-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010004319-A1 | COMBINATION COMPRISING 6-FLU0R0-N- ((1S, 4S) - 4- (6-FLUORO-2, 4-DI0X0-1- (4'- (PIPERAZIN-1- YLMETHYL) BIPHENYL- 3-YL) -1, 2-DIHYDROPYRIDO [2, 3-D] PYRIMIDIN-3 (4H) - YL) CYCLOHEXYL) IMIDAZO [1,2-A] PYRIDINE -2- CARBOXAMIDE OR A SALT | ASTRAZENECA AB (SE) | 2010-01-14 | — | — | WO | disclosed |
| WO-2009154562-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A 4-HYDROXY-2-OXO-2, 3- DIHYDRO-1, 3-BENZOTHIAZOL-7-YL COMPOUND FOR MODULATION OF BETA2-ADRENORECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
| US-20090176751-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS | GRAS ESCARDO JORDI | 2009-07-09 | — | — | US | disclosed |
| WO-2009037503-A2 | NEW COMBINATION - 012 FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2009-03-26 | — | — | WO | disclosed |
| WO-2008096121-A1 | COMBINATIONS OF BETA-2-ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261690-A1 | NOVEL COMBINATIONS | ADRB2, NR3C2, GRK4 | CHRM3 21/4885CHRM2 33/4885CHRM1 150/4885 |
| US-20090176751-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS | CHRM3, ADRB2, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.